Moreover, they express higher levels of TAM-related markers (CD206, MerTK and CD163), compared to blood circulating CD14+ DCs, we previously linked to lower immunological response to DC-based vaccines in melanoma patients23,26. This evidence concerns the gene CD163 and melanoma.